← Back to Search

Ancillary-Correlative (tissue sample collection) for Lymphoma

N/A
Waitlist Available
Led By Charles P Reynolds
Research Sponsored by Children's Oncology Group
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 14 years
Awards & highlights

Summary

This laboratory study is collecting and storing tissue, blood, and bone marrow samples from young patients with cancer. Collecting and storing samples of tissue, blood, and bone marrow from patients with cancer to study in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.

Eligible Conditions
  • Cancer
  • Lymphoma
  • Osteosarcoma
  • Rhabdomyosarcoma
  • Leukemia
  • Soft Tissue Sarcoma
  • Retinoblastoma
  • Rhabdoid Tumor
  • Neuroblastoma
  • Germ Cell Tumors
  • Acute Lymphoblastic Leukemia
  • Acute Myeloid Leukemia
  • Brain Tumor
  • Ewing Sarcoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 14 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 14 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Characterization of cell lines for expression of molecular makers that confirm the tumor-type of the cell line and the immortal nature of the cells (telomerase) and the expression of molecular markers that may correlate with drug resistance
Characterization of cell lines for mycoplasma contamination
Characterization of cell lines for the ability for sustained growth in tissue culture and/or as mouse xenografts
+5 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Ancillary-Correlative (tissue sample collection)Experimental Treatment2 Interventions
Leftover tissue from diagnostic procedures and/or surgery is cryopreserved and banked. Blood and/or bone marrow are also collected and banked. Cell lines are established and characterized via reverse-transcriptase polymerase chain reaction and/or flow cytometry for biomarkers and by DNA fingerprinting. Markers to be identified may include the following: NEUROBLASTOMA: tyrosine hydroxylase, protein gene product (PGP) 9.5, GD2, HLA class I, and HSAN 1.2 antigens EWING FAMILY OF TUMORS: EWS-FLI1, EWS-ERG, and PGP 9.5 RETINOBLASTOMA: interphotoreceptor retinoid-binding protein ACUTE LYMPHOBLASTIC LEUKEMIA: immunophenotype ALVEOLOR RHADOMYOSARCOMA: PAX3-FKHR, PAX7-FKHR, and MyoD1 ALL CELL TYPES: telomerase expression including hTR and hTERTMutations of TP53 gene are detected by flow cytometry and/or immunocytochemistry

Find a Location

Who is running the clinical trial?

Children's Oncology GroupLead Sponsor
457 Previous Clinical Trials
239,617 Total Patients Enrolled
62 Trials studying Lymphoma
23,852 Patients Enrolled for Lymphoma
National Cancer Institute (NCI)NIH
13,841 Previous Clinical Trials
41,002,676 Total Patients Enrolled
1,399 Trials studying Lymphoma
382,650 Patients Enrolled for Lymphoma
Charles P ReynoldsPrincipal InvestigatorChildren's Oncology Group
~14 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top